Efficacy of Lenvatinib and Atezolizumab Bevacizumab Combination Therapy in Patients With Combined Hepatocellular-cholangiocarcinoma.

BACKGROUND/AIM: Surgical resection remains the only curative treatment for combined hepatocellular-cholangiocarcinoma; however, systemic therapy is the primary treatment option for unresectable cases. This multicenter retrospective study aimed to assess the efficacy of systemic therapy for unresectable combined hepatocellular-cholangiocarcinoma.

PATIENTS AND

METHODS

Twenty-one patients with histologically confirmed or clinically diagnosed combined hepatocellular-cholangiocarcinoma who received systemic therapy were included. First-line regimens consisted of lenvatinib (n=14) and atezolizumab plus bevacizumab (n=7) and their therapeutic efficacy was evaluated.

RESULTS

The objective response and disease control rates were 42.9% and 92.9% for lenvatinib, and 14.3% and 100% for atezolizumab plus bevacizumab, respectively. Median overall survival for all treatments was 14.9 months and median progression-free survival was 6.5 months. By regimen, median overall and progression-free survival was 14.9 and 6.1 months for lenvatinib, and "not reached" and 7.9 months for atezolizumab plus bevacizumab, respectively.

CONCLUSION

Lenvatinib and atezolizumab plus bevacizumab exhibited potential activity in patients with combined hepatocellular-cholangiocarcinoma.